Prn Budesonide/Formoterol Versus Regular Budesonide/Formoterol Plus Prn Terbutaline in Mild-Moderate Asthma
Primary Purpose
Asthma
Status
Completed
Phase
Phase 3
Locations
Italy
Study Type
Interventional
Intervention
budesonide/formoterol combination (PRN)
budesonide/formoterol combination
placebo
terbutaline
Sponsored by

About this trial
This is an interventional treatment trial for Asthma focused on measuring Adult, Asthma, Bronchodilator Agents, Budesonide, Double-Blind Method, Drug Therapy, Combination, Ethanolamines, Female, Forced Expiratory Volume, Humans, Male, Terbutaline
Eligibility Criteria
Inclusion Criteria:
- Male or female out-patient aged from 18 years to 65 years
- Clinical diagnosis of moderate persistent asthma for at least 6 months, according to GINA revised version 2006 guidelines
- Post-bronchodilator forced expiratory volume (FEV1) at least 80% of the predicted
- Either positive methacholine challenge test (PC20 FEV1< 4mg/ml or PD20 FEV1<0.8 mg) or positive response to the reversibility test in the last year
- Asthma either not adequately controlled with low-dose (≤500 mcg beclomethasone or equivalent) inhaled corticosteroids (ICS) or controlled by bid inhaled combination of low-dose ICS/long acting beta-2 agonists (LABA)
- A co-operative attitude and ability to be trained to correctly use the dry powder inhalator and to complete the diary cards
- Written informed consent obtained
Exclusion Criteria:
- Inability to carry out pulmonary function testing
- Moderate severe asthma associated with reduced lung function
- History of near-fatal asthma and/or admission intensive care unit because of asthma
- 3 or more courses of oral corticosteroids or hospitalization for asthma during the previous year
- Diagnosis of COPD as defined by the GOLD guidelines
- Evidence of severe asthma exacerbation or symptomatic infection of the airways in the previous 8 weeks
- Current smokers or recent (less than one year) ex-smokers, defined as smoking at least 10 pack/years
- History or current evidence of heart failure, coronary artery disease, myocardial infarction, severe hypertension, or cardiac arrhythmias
- Diabetes mellitis
- Percutaneous transluminal coronary angioplasty (PTCA) or coronary artery by-pass graft (CABG) during the previous six months
- Abnormal ECG
- Clinically significant or unstable concurrent diseases: uncontrolled hyperthyroidism, significant hepatic impairment, poorly controlled pulmonary disease (tuberculosis, active mycotic infection of the lung), gastrointestinal (e.g., active peptic ulcer), neurological or haematological autoimmune diseases
- Malignancy
- Any chronic diseases with prognosis < 2 years
- Pregnant or lactating females or not able to exclude pregnancy during the study period
- History of alcohol or drug abuse
- Patients treated with monoamine oxidase inhibitors, tricyclic antidepressants or beta-blockers as regular use
- Allergy, sensitivity or intolerance to study drugs and/or study drug formulation ingredients
- Patients unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study
- Patients who received any investigational new drug within the last 12 weeks
- Patients who have been previously enrolled in this study
Sites / Locations
- Ospedale regionale Umberto I, Unità Operativa di Allergologia
- Fondazione S. Maugeri - IRCCS -dipartimento di Pneumologia riabilitativa
- Dipartimento di Scienze Mediche-Unità Operativa di Pneumologia
- Policlinico Sant'Orsola Malpighi, Unità Operativa di Pneumologia
- Università degli Studi di Catania, Unità operativa di Pneumologia
- Università Magna Grecia Catanzaro, unità operativa di Pneumologia
- Ospedale Morgagni Pierantoni, azienda Ospedaliera di Forlì, Unitaà operativa di Pneumologia
- UNIVERSITà DEGLI STUDI DI FERRARA, CLINICA DI MALATTIE DELL'APPARATO RESPIRATORIO
- Università degli studi di Foggia, ospedale pneumologico D'Avanzo, unità operativa di malattie dell'apparato respiratorio
- Ospadale San Carlo Borromeo - Unità operativa di Pneumologia
- Ospedale città di Sesto San Giovanni, Unità operativa di Pneumologia
- Università di Modena e Reggio Emilia, Unità operativa di Pneumologia
- Università degli Studi di Palermo, Ospedale "V. Cervello"
- Università degli studi di Padova, dipartimento di Pneunmologia
- Università degli studi di Padova, Medicina del Lavoro
- Università degli studi di Pisa, Ospedale Cisanello, unità operativa di Pneumologia
- Università degli stiudi di Parma, unità operativa di Pneumologia
- IRCCS Fondazione S Maugeri, Dipartimento di Allergologia
- Università degli studi di Pavia, dipartimento di Pneumologia
- università Cattolica del Sacro Cuore, Columbus, unità operativa di allergologia
- Università Cattolica del Sacro Cuore, Policlinico Gemelli, unità operativa di Pneumologia
- Università Roma La Sapienza, servizio di Fisiopatologia respiratoria
- Università di Perugia -Terni, Medcina del lavoro Terni
- Università degli studi di Torino, Dipartimento di scienze biomediche ed oncologia umana
- Ospedale di Cattinara, unità operativa di pneumologia
- Ospedale di Bussolengo, Unità operativa di Pneumologia
- azienda universitaria-ospedaliera istituti ospitalieri di Verona, unità operativa di Allergologia
- Servizio Pneumologico ASL Brindisi
- Seconda Università degli stuidi di Napoli, unità Operativa di Pneumologia
- Giuseppina Bertorelli
- Università di Roma Tor Vergata, unità di malattie dell'apparato Respiratorio
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
as needed medication
guideline treatment
Arm Description
patients assigned to this arm will take bid inhaled placebo plus prn inhaled 160/4.5 mcg budesonide/formoterol combination
bid inhaled 160/4.5 mcg budesonide/formoterol combination plus prn 500 mcg terbutaline
Outcomes
Primary Outcome Measures
comparison between groups of the relative risk for treatment failure
Secondary Outcome Measures
number of treatment failures
time to first treatment failure
differences between groups of lung function parameters, quality of life, symptoms score, use of as needed medication, adverse events
Full Information
NCT ID
NCT00849095
First Posted
February 20, 2009
Last Updated
May 29, 2014
Sponsor
Università degli Studi di Ferrara
1. Study Identification
Unique Protocol Identification Number
NCT00849095
Brief Title
Prn Budesonide/Formoterol Versus Regular Budesonide/Formoterol Plus Prn Terbutaline in Mild-Moderate Asthma
Official Title
As Needed Budesonide/Formoterol Combination Versus Regular Budesonide/Formoterol Combination Plus as Needed Terbutaline in Mild-Moderate Persistent Asthma
Study Type
Interventional
2. Study Status
Record Verification Date
May 2014
Overall Recruitment Status
Completed
Study Start Date
April 2009 (undefined)
Primary Completion Date
April 2013 (Actual)
Study Completion Date
May 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Università degli Studi di Ferrara
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Study No.001 about Budesonide/Formoterol use in ASthMA sponsored by Agenzia Italiana del FArmaco (Italian Drug Agency) (AIFA-ASMA-BF-001) The aim of the study is to verify whether asthma not controlled by low doses inhaled corticosteroids, thus in need for step up therapy, can be equally controlled by guidelines recommended regular bid treatment with long acting beta agonist/inhaled corticosteroid (ICS/LABA) combination or the symptom driven use of an ICS/LABA combination in the absence of maintenance therapy. The study is designed to be able to evaluate the non inferiority of regular placebo plus prn inhaled budesonide/formoterol (experimental treatment) versus regular, twice daily 160/4.5 mcg inhaled budesonide/formoterol combination plus prn inhaled terbutaline (guidelines recommended treatment).
Detailed Description
Asthma is a problem worldwide, with an estimated 300 million affected individuals.There is evidence that asthma prevalence has been increasing in the last decades in some countries, including Italy. Analyses of the cost of asthma lead to conclude that the burden of the disease depend on the extent to which exacerbations are avoided since emergency treatment is more expensive than regular treatment.
Based on solid evidence, international guidelines recommend regular treatment with low dose ICS for mild persistent asthma and treatment with combination therapy [low dose ICS plus long-acting beta2-agonists (LABA)] for patients with asthma not controlled by low doses ICS alone. Recent studies have undermined the axiom that treatment with ICS must be regular to achieve and maintain asthma control, as equivalent control has been obtained either with prn use of an inhaled combination of a short acting beta2 agonist (SABA) and an ICS, or with a short course of 10 days high dose ICS at the start of exacerbations. In moderate-severe asthma regularly treated with inhaled ICS/LABA combination, the symptom-driven use of the same inhaled ICS/LABA combination as reliever is superior to the symptom-driven use of SABA or LABA alone.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
Adult, Asthma, Bronchodilator Agents, Budesonide, Double-Blind Method, Drug Therapy, Combination, Ethanolamines, Female, Forced Expiratory Volume, Humans, Male, Terbutaline
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
860 (Actual)
8. Arms, Groups, and Interventions
Arm Title
as needed medication
Arm Type
Experimental
Arm Description
patients assigned to this arm will take bid inhaled placebo plus prn inhaled 160/4.5 mcg budesonide/formoterol combination
Arm Title
guideline treatment
Arm Type
Active Comparator
Arm Description
bid inhaled 160/4.5 mcg budesonide/formoterol combination plus prn 500 mcg terbutaline
Intervention Type
Drug
Intervention Name(s)
budesonide/formoterol combination (PRN)
Other Intervention Name(s)
budesonide/formoterol combination
Intervention Description
budesonide/formoterol combination 160/4.5 mcg 1 inhalation used as needed for a period of 52 weeks
Intervention Type
Drug
Intervention Name(s)
budesonide/formoterol combination
Intervention Description
budesonide/formoterol 160/4.5 mcg 1 inhalation bid
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
bid inhaled placebo
Intervention Type
Drug
Intervention Name(s)
terbutaline
Intervention Description
as needed terbutaline 500 mcg for a period of 52 weeks
Primary Outcome Measure Information:
Title
comparison between groups of the relative risk for treatment failure
Time Frame
52 weeks
Secondary Outcome Measure Information:
Title
number of treatment failures
Time Frame
52 weeks
Title
time to first treatment failure
Time Frame
52 weeks
Title
differences between groups of lung function parameters, quality of life, symptoms score, use of as needed medication, adverse events
Time Frame
52 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or female out-patient aged from 18 years to 65 years
Clinical diagnosis of moderate persistent asthma for at least 6 months, according to GINA revised version 2006 guidelines
Post-bronchodilator forced expiratory volume (FEV1) at least 80% of the predicted
Either positive methacholine challenge test (PC20 FEV1< 4mg/ml or PD20 FEV1<0.8 mg) or positive response to the reversibility test in the last year
Asthma either not adequately controlled with low-dose (≤500 mcg beclomethasone or equivalent) inhaled corticosteroids (ICS) or controlled by bid inhaled combination of low-dose ICS/long acting beta-2 agonists (LABA)
A co-operative attitude and ability to be trained to correctly use the dry powder inhalator and to complete the diary cards
Written informed consent obtained
Exclusion Criteria:
Inability to carry out pulmonary function testing
Moderate severe asthma associated with reduced lung function
History of near-fatal asthma and/or admission intensive care unit because of asthma
3 or more courses of oral corticosteroids or hospitalization for asthma during the previous year
Diagnosis of COPD as defined by the GOLD guidelines
Evidence of severe asthma exacerbation or symptomatic infection of the airways in the previous 8 weeks
Current smokers or recent (less than one year) ex-smokers, defined as smoking at least 10 pack/years
History or current evidence of heart failure, coronary artery disease, myocardial infarction, severe hypertension, or cardiac arrhythmias
Diabetes mellitis
Percutaneous transluminal coronary angioplasty (PTCA) or coronary artery by-pass graft (CABG) during the previous six months
Abnormal ECG
Clinically significant or unstable concurrent diseases: uncontrolled hyperthyroidism, significant hepatic impairment, poorly controlled pulmonary disease (tuberculosis, active mycotic infection of the lung), gastrointestinal (e.g., active peptic ulcer), neurological or haematological autoimmune diseases
Malignancy
Any chronic diseases with prognosis < 2 years
Pregnant or lactating females or not able to exclude pregnancy during the study period
History of alcohol or drug abuse
Patients treated with monoamine oxidase inhibitors, tricyclic antidepressants or beta-blockers as regular use
Allergy, sensitivity or intolerance to study drugs and/or study drug formulation ingredients
Patients unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study
Patients who received any investigational new drug within the last 12 weeks
Patients who have been previously enrolled in this study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alberto Papi, MD
Organizational Affiliation
Università degli Studi di Ferrara
Official's Role
Principal Investigator
Facility Information:
Facility Name
Ospedale regionale Umberto I, Unità Operativa di Allergologia
City
Ancona
State/Province
AN
Country
Italy
Facility Name
Fondazione S. Maugeri - IRCCS -dipartimento di Pneumologia riabilitativa
City
Cassano delle Murge
State/Province
BA
Country
Italy
Facility Name
Dipartimento di Scienze Mediche-Unità Operativa di Pneumologia
City
Benevento
State/Province
BN
ZIP/Postal Code
82100
Country
Italy
Facility Name
Policlinico Sant'Orsola Malpighi, Unità Operativa di Pneumologia
City
Bologna
State/Province
BO
Country
Italy
Facility Name
Università degli Studi di Catania, Unità operativa di Pneumologia
City
Catania
State/Province
CT
Country
Italy
Facility Name
Università Magna Grecia Catanzaro, unità operativa di Pneumologia
City
Catanzaro
State/Province
CZ
Country
Italy
Facility Name
Ospedale Morgagni Pierantoni, azienda Ospedaliera di Forlì, Unitaà operativa di Pneumologia
City
Forlì
State/Province
FC
Country
Italy
Facility Name
UNIVERSITà DEGLI STUDI DI FERRARA, CLINICA DI MALATTIE DELL'APPARATO RESPIRATORIO
City
Ferrara
State/Province
FE
ZIP/Postal Code
44100
Country
Italy
Facility Name
Università degli studi di Foggia, ospedale pneumologico D'Avanzo, unità operativa di malattie dell'apparato respiratorio
City
Foggia
State/Province
FG
Country
Italy
Facility Name
Ospadale San Carlo Borromeo - Unità operativa di Pneumologia
City
Milano
State/Province
MI
Country
Italy
Facility Name
Ospedale città di Sesto San Giovanni, Unità operativa di Pneumologia
City
Sesto San Giovanni
State/Province
MI
Country
Italy
Facility Name
Università di Modena e Reggio Emilia, Unità operativa di Pneumologia
City
Modena
State/Province
MO
Country
Italy
Facility Name
Università degli Studi di Palermo, Ospedale "V. Cervello"
City
Palermo
State/Province
Pa
ZIP/Postal Code
90146
Country
Italy
Facility Name
Università degli studi di Padova, dipartimento di Pneunmologia
City
Padova
State/Province
PD
Country
Italy
Facility Name
Università degli studi di Padova, Medicina del Lavoro
City
Padova
State/Province
PD
Country
Italy
Facility Name
Università degli studi di Pisa, Ospedale Cisanello, unità operativa di Pneumologia
City
Pisa
State/Province
PI
Country
Italy
Facility Name
Università degli stiudi di Parma, unità operativa di Pneumologia
City
Parma
State/Province
PR
Country
Italy
Facility Name
IRCCS Fondazione S Maugeri, Dipartimento di Allergologia
City
Pavia
State/Province
PV
Country
Italy
Facility Name
Università degli studi di Pavia, dipartimento di Pneumologia
City
Pavia
State/Province
PV
Country
Italy
Facility Name
università Cattolica del Sacro Cuore, Columbus, unità operativa di allergologia
City
Roma
State/Province
RM
Country
Italy
Facility Name
Università Cattolica del Sacro Cuore, Policlinico Gemelli, unità operativa di Pneumologia
City
Roma
State/Province
RM
Country
Italy
Facility Name
Università Roma La Sapienza, servizio di Fisiopatologia respiratoria
City
Roma
State/Province
RM
Country
Italy
Facility Name
Università di Perugia -Terni, Medcina del lavoro Terni
City
Terni
State/Province
TI
Country
Italy
Facility Name
Università degli studi di Torino, Dipartimento di scienze biomediche ed oncologia umana
City
Torino
State/Province
TO
Country
Italy
Facility Name
Ospedale di Cattinara, unità operativa di pneumologia
City
Trieste
State/Province
TS
Country
Italy
Facility Name
Ospedale di Bussolengo, Unità operativa di Pneumologia
City
Bussolengo
State/Province
VR
Country
Italy
Facility Name
azienda universitaria-ospedaliera istituti ospitalieri di Verona, unità operativa di Allergologia
City
Verona
State/Province
VR
Country
Italy
Facility Name
Servizio Pneumologico ASL Brindisi
City
Brindisi
Country
Italy
Facility Name
Seconda Università degli stuidi di Napoli, unità Operativa di Pneumologia
City
Napoli
Country
Italy
Facility Name
Giuseppina Bertorelli
City
Parma
ZIP/Postal Code
43100
Country
Italy
Facility Name
Università di Roma Tor Vergata, unità di malattie dell'apparato Respiratorio
City
Roma
Country
Italy
12. IPD Sharing Statement
Citations:
PubMed Identifier
25481378
Citation
Papi A, Marku B, Scichilone N, Maestrelli P, Paggiaro P, Saetta M, Nava S, Folletti I, Bertorelli G, Bertacco S, Contoli M, Plebani M, Barbaro MPF, Spanevello A, Aliani M, Pannacci M, Morelli P, Beghe B, Fabbri LM; AIFASMA Study Group. Regular versus as-needed budesonide and formoterol combination treatment for moderate asthma: a non-inferiority, randomised, double-blind clinical trial. Lancet Respir Med. 2015 Feb;3(2):109-119. doi: 10.1016/S2213-2600(14)70266-8. Epub 2014 Dec 4.
Results Reference
derived
Learn more about this trial
Prn Budesonide/Formoterol Versus Regular Budesonide/Formoterol Plus Prn Terbutaline in Mild-Moderate Asthma
We'll reach out to this number within 24 hrs